OR WAIT null SECS
Regeneron Pharmaceuticals’ new treatment for visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO) has been approved by the European Commission.
Tarrytown, NY-Regeneron Pharmaceuticals’ new treatment for visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO) has been approved by the European Commission.
Aflibercept (EYLEA) was approved in the United States for the treatment of neovascular (wet) age-related macular degeneration (AMD) in 2011, and for macular edema following CRVO in 2012.
“We are pleased with the approval of (aflibercept) in the European Union in a second indication,” said George D. Yancopoulos, MD, PhD, chief scientific officer of Regeneron and president of Regeneron Laboratories. “Our phase III studies showed that (the injection) improved visual outcomes significantly… this additional approval of (aflibercept) is great news for patients in Europe.”
Aflibercept has also been approved in Europe, Japan, Australia, and in several other countries for use in wet AMD and in selected countries in South American for macular edema following CRVO.
For more articles in this issue of Ophthalmology Times eReport, click here.
To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.